Literature DB >> 20411433

CEA-antigen and SCC-antigen mRNA expression in peripheral blood predict hematogenous recurrence after resection in patients with esophageal cancer.

Koji Tanaka1, Masahiko Yano, Masaaki Motoori, Kentaro Kishi, Isao Miyashiro, Tatsushi Shingai, Kunihito Gotoh, Shingo Noura, Hidenori Takahashi, Masayuki Ohue, Terumasa Yamada, Hiroaki Ohigashi, Takashi Yamamoto, Tomoyuki Yamasaki, Yuichiro Doki, Osamu Ishikawa.   

Abstract

BACKGROUND: Although several studies have suggested an association between circulating tumor cells (CTC) and prognosis after esophageal cancer surgery, large-scale studies are lacking. The aim of this study was to prospectively examine the correlation between CTC and outcome in a large number of patients who underwent esophagectomy.
MATERIALS AND METHODS: A cohort of 244 patients with squamous cell carcinoma of the esophagus who underwent curative surgery between 2002 and 2007 were prospectively analyzed for CTC before surgery and after the thoracic procedure. Reverse transcription-polymerase chain reaction for CEA and SCC antigen mRNA was used to detect cancer cells in the peripheral blood. CTC was defined as positive when at least 1 tumor marker mRNA was detected.
RESULTS: CTC was positive in 34 patients (13.9%) before surgery and in 41 patients (16.8%) after the thoracic procedure. Multivariate analysis identified tumor depth (hazard ratio [HR], 0.439; 95% confidence interval [95% CI], 0.268-0.722; P = 0.0012), lymph node metastasis (HR, 2.467; 95% CI, 1.436-4.237; P = 0.0011), venous invasion (HR, 1.802; 95% CI, 1.082-3.002; P = 0.0236), and CTC status after the thoracic procedure (HR, 1.647; 95% CI, 1.032-2.629; P = 0.0365) as independent prognostic factors of disease-free survival. The rates of hematogenous (P = 0.0222) and local (P = 0.0464) recurrences were significantly higher in patients with CTC(+) after the thoracic procedure than those with CTC(-) after the thoracic procedure. Responders to neoadjuvant chemotherapy showed less lymphatic invasion and a decreased positive CTC rate after the thoracic procedure than nonresponders.
CONCLUSIONS: CTC status after the thoracic procedure is a useful predictor for hematogenous and local recurrences in patients with esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20411433     DOI: 10.1245/s10434-010-1075-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  [Prognostic value of circulating tumor cells and disseminated tumor cells in patients with esophageal cancer: a meta-analysis].

Authors:  Xiao-Xin Shi; Jian-Hong An; Ye-En Huang; Yao-Zhong Zhang; Zhuo-Ya Huang; Zhen-Ning Zou; Qing Chen; Hong Shen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-02-20

2.  Identification of potential plasma biomarkers for esophageal squamous cell carcinoma by a proteomic method.

Authors:  Jia Zhao; Yu-Xia Fan; Yang Yang; Dong-Lei Liu; Kai Wu; Feng-Biao Wen; Chun-Yang Zhang; Deng-Yan Zhu; Song Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  The Significance of SCC and CEA mRNA in the Pleural Cavity After Lymphadenectomy in Esophageal Cancer Patients who Underwent Preoperative Treatment.

Authors:  Keijiro Sugimura; Hiroshi Miyata; Masaaki Motoori; Takeshi Omori; Yoshiyuki Fujiwara; Masahiko Yano
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

4.  Combining proteomics, serum biomarkers and bioinformatics to discriminate between esophageal squamous cell carcinoma and pre-cancerous lesion.

Authors:  Xiao-hui Zhai; Jie-kai Yu; Chen Lin; Li-dong Wang; Shu Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2012-12       Impact factor: 3.066

5.  Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma.

Authors:  Xun Cao; Lin Zhang; Gui-Rong Feng; Juan Yang; Ruo-Yan Wang; Jun Li; Xiao-Min Zheng; Yu-Jing Han
Journal:  J Transl Med       Date:  2012-09-21       Impact factor: 5.531

6.  Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation.

Authors:  Feng-Ming Hsu; Jason Chia-Hsien Cheng; Yih-Leong Chang; Jang-Ming Lee; Albert C Koong; Eric Y Chuang
Journal:  Sci Rep       Date:  2015-05-18       Impact factor: 4.379

7.  Prognostic value of circulating tumor cells in esophageal cancer.

Authors:  Hai-Tao Xu; Jing Miao; Jian-Wei Liu; Lian-Guo Zhang; Qing-Guang Zhang
Journal:  World J Gastroenterol       Date:  2017-02-21       Impact factor: 5.742

8.  Significant prognostic value of circulating tumor cells in esophageal cancer patients: A meta-analysis.

Authors:  Shuyu Wang; Hongyang Du; Guixia Li
Journal:  Oncotarget       Date:  2017-02-28

9.  Prognostic significance of circulating tumor cells in esophageal carcinoma: a meta-analysis.

Authors:  Guang-Lei Qiao; Wei-Xiang Qi; Wei-Hua Jiang; Ying Chen; Li-Jun Ma
Journal:  Onco Targets Ther       Date:  2016-03-31       Impact factor: 4.147

10.  Circulating Tumor Cell Analyses in Patients With Esophageal Squamous Cell Carcinoma Using Epithelial Marker-Dependent and -Independent Approaches.

Authors:  Hao Li; Pingping Song; Benkui Zou; Min Liu; Kai Cui; Pengfei Zhou; Sheng Li; Baijiang Zhang
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.